© 2020 American Regent, Inc. A Daiichi Sankyo Gr

© 2020 American Regent, Inc.
A Daiichi Sankyo Group Company
https://dsi.com/home

Interesting that the parent is involved in cancer reaserch among others...


Press Releases
Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer
Download the PDF version of Article

July 01, 2020



Phase 1 study now evaluating DS-1062, a TROP2 directed DXd ADC, in patients with advanced/ unresectable or metastatic triple negative breast cancer
Expansion follows encouraging preliminary results for DS-1062 in patients with advanced non-small cell lung cancer
Tokyo, Munich and Basking Ridge, NJ – (July 1, 2020) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the first patient with triple negative breast cancer (TNBC) has been dosed in the ongoing phase 1 study assessing DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC).

Patients with TNBC, an aggressive subtype of breast cancer, have limited treatment options beyond standard chemotherapy.1 High TROP2 expression has been reported in up to 80 percent of patients with TNBC.2,3